Bluejay Diagnostics (BJDX) director buys 12,500 shares in placement

Rhea-AI Filing Summary

Bluejay Diagnostics director Svetlana Dey bought additional company stock. On March 14, 2026, she purchased 12,500 shares of Bluejay Diagnostics common stock from the company in a private placement at $2.00 per share.

After this transaction, Ms. Dey directly owns 12,501 common shares and indirectly controls 127 common shares held through Lana Management & Business Research International, LLC, over which she has voting and dispositive power.

Insider Trade Summary

Net Buyer: 12,500 shares ($25,000)

Net Buy 2 txns

Insider Dey Svetlana

Role null

Bought 12,500 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,500	$2.00	$25K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 12,501 shares (Direct, null); Common Stock — 127 shares (Indirect, Held by Lana Management & Business Research International, LLC)

Footnotes (1)

1. On March 14, 2026, Ms. Dey purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share. Lana Management & Business Research International, LLC is an entity owned by Mr. Indranil Dey and Ms. Svetlana Dey. Ms. Dey has voting and dispositive power over the shares held by such entity.

Key Figures

Shares purchased: 12,500 shares Purchase price: $2.00 per share Direct holdings after transaction: 12,501 shares +1 more

4 metrics

Shares purchased 12,500 shares Common Stock bought on March 14, 2026

Purchase price $2.00 per share Private placement with issuer

Direct holdings after transaction 12,501 shares Common Stock directly owned by Svetlana Dey

Indirect holdings after transaction 127 shares Held via Lana Management & Business Research International, LLC

Key Terms

private placement, voting and dispositive power, Common Stock

3 terms

private placement financial

"purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

voting and dispositive power financial

"Ms. Dey has voting and dispositive power over the shares held by such entity"

Common Stock financial

"On March 14, 2026, Ms. Dey purchased 12,500 shares of the issuer's common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dey Svetlana

(Last) (First) (Middle)

C/O BLUEJAY DIAGNOSTICS, INC.

360 MASSACHUSETTS AVENUE, SUITE 203

(Street)

ACTON MASSACHUSETTS 01720

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bluejay Diagnostics, Inc. [ BJDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/14/2026		P		12,500(1)	A	$2	12,501	D
Common Stock								127	I	Held by Lana Management & Business Research International, LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 14, 2026, Ms. Dey purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share.

2. Lana Management & Business Research International, LLC is an entity owned by Mr. Indranil Dey and Ms. Svetlana Dey. Ms. Dey has voting and dispositive power over the shares held by such entity.

	/s/ Svetlana Dey	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Bluejay Diagnostics (BJDX) report for Svetlana Dey?

Bluejay Diagnostics reported that director Svetlana Dey purchased 12,500 common shares. The shares were acquired on March 14, 2026 in a private placement directly from the company at $2.00 per share, increasing her direct ownership stake.

At what price did Svetlana Dey buy Bluejay Diagnostics (BJDX) shares?

Svetlana Dey bought Bluejay Diagnostics common stock at $2.00 per share. She acquired 12,500 shares in a private placement from the issuer on March 14, 2026, reflecting a direct cash investment into the company at that fixed price.

How many Bluejay Diagnostics (BJDX) shares does Svetlana Dey own after the Form 4 transaction?

After the transaction, Svetlana Dey directly owns 12,501 common shares of Bluejay Diagnostics. In addition, she has voting and dispositive power over 127 common shares held indirectly through Lana Management & Business Research International, LLC.

Was the Bluejay Diagnostics (BJDX) insider purchase an open-market trade?

No. The 12,500-share purchase by Svetlana Dey was a private placement from the issuer. Although coded as a purchase, the footnote clarifies the shares were acquired directly from Bluejay Diagnostics rather than through the open market.

What is Lana Management & Business Research International, LLC’s role in Bluejay Diagnostics (BJDX) holdings?

Lana Management & Business Research International, LLC holds 127 Bluejay Diagnostics common shares. The entity is owned by Indranil and Svetlana Dey, and Svetlana Dey has voting and dispositive power over the shares held by this LLC.